Palvella Therapeutics (NASDAQ:PVLA) Announces Earnings Results

Palvella Therapeutics (NASDAQ:PVLA) posted its earnings results on Tuesday. The company reported ($1.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.17) by ($0.35), Zacks reports.

Here are the key takeaways from Palvella Therapeutics’ conference call:

• QTORIN rapamycin’s NDA remains on track for completion in the second half of 2026, with potential FDA approval in the first half of 2027. FDA granted rolling review, supported by the product’s Fast Track and Breakthrough Therapy designations.
• The company highlighted strong phase III SELVA results in microcystic lymphatic malformations, including improvement in 95% of patients at week 24 and a favorable safety profile. Palvella plans to pursue a broad label that includes pediatric patients and is targeting a potential first-line therapy.
• Palvella is expanding its commercial infrastructure ahead of a potential launch, including increasing its planned sales force to approximately 40 representatives, building medical affairs and patient-support teams, and engaging more than 200 of 400 targeted clinics.
• The pipeline continues to advance, with a phase III study in cutaneous venous malformations expected to begin in the fourth quarter of 2026, a phase II angiokeratoma study already underway, and a phase II DSAP study expected to start in the fourth quarter. The company expects additional QTORIN program announcements later this year.
• FDA did not grant Breakthrough Therapy Designation for the cutaneous venous malformation program based on the initial 12-week data package. Palvella plans to resubmit using 24-week efficacy results and qualitative patient data, while increased commercial and medical investments raised expected 2026 cash expenses to approximately $85 million-$95 million.

Palvella Therapeutics Price Performance

Shares of NASDAQ:PVLA traded up $5.84 during midday trading on Tuesday, hitting $146.62. The company had a trading volume of 64,446 shares, compared to its average volume of 277,204. The company has a fifty day moving average of $130.73 and a two-hundred day moving average of $118.68. The company has a market cap of $2.10 billion, a price-to-earnings ratio of -35.16 and a beta of -0.17. Palvella Therapeutics has a 12-month low of $36.93 and a 12-month high of $161.38.

Insider Activity

In other news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total transaction of $476,360.46. Following the sale, the chief operating officer directly owned 2,154 shares in the company, valued at $238,512.42. This trade represents a 66.64% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Palvella Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in shares of Palvella Therapeutics by 202.0% in the third quarter. Vanguard Group Inc. now owns 494,656 shares of the company’s stock worth $31,010,000 after buying an additional 330,847 shares in the last quarter. State Street Corp increased its holdings in Palvella Therapeutics by 206.3% in the 4th quarter. State Street Corp now owns 420,462 shares of the company’s stock valued at $44,010,000 after acquiring an additional 283,211 shares during the last quarter. Millennium Management LLC bought a new stake in Palvella Therapeutics in the 1st quarter valued at $7,553,000. Artisan Partners Limited Partnership purchased a new stake in Palvella Therapeutics in the 4th quarter worth $22,143,000. Finally, First Light Asset Management LLC lifted its stake in Palvella Therapeutics by 30.9% in the 4th quarter. First Light Asset Management LLC now owns 709,141 shares of the company’s stock worth $74,226,000 after purchasing an additional 167,597 shares in the last quarter. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on PVLA. HC Wainwright restated a “buy” rating and issued a $270.00 target price on shares of Palvella Therapeutics in a report on Wednesday, July 22nd. Chardan Capital raised Palvella Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Stephens restated an “overweight” rating and issued a $220.00 price target on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Wall Street Zen lowered Palvella Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 11th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Palvella Therapeutics in a report on Monday, June 29th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Palvella Therapeutics currently has an average rating of “Buy” and a consensus target price of $207.36.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.